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ABSTRACT
Prader-Willi syndrome (PWS) is a chromo-
somal disorder and growth failure is a common
presentation. Growth hormone (GH) treatment
is beneficial in PWS although the optimal age
for starting GH is unknown. We investigated
whether GH response in PWS was associated
with the age of GH commencement by com-
paring 16 children who commenced GH before 3
years of age (early group) with 40 children who
commenced GH after 3 years of age (late group)
from the Ozgrow database. Height SDS, body
mass index (BMI) SDS, bone age (BA)-chrono-
logical age (CA) ratio, change in height (Δ Ht)
SDS and change in BMI during 4 years of GH
treatment were compared between the groups.
The early group had better height SDS and Δ Ht
SDS. BA delay was more pronounced in the
early group but BA did not mature beyond CA
with GH therapy in either group. Although the
initial GH dose for the early group was lower
than that of the late group, the former had
better height outcome. The starting GH dose
seen in the database is lower than the dose used
by international centres.
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INTRODUCTION
Prader-Willi syndrome (PWS) is a genetic dis-
order characterised by growth failure, hypogonado-
trophic hypogonadism, hypotonia, sleep-related
breathing disorders, developmental delay, behavi-
oural problems, hyperphagia and obesity . It is due
to loss' of1 imprinted gene expression from the
paternal chromosome 15qll-ql3 region. Normally
paternally inherited genes in this region are ex-
pressed while maternal genes are inactivated. Loss
of expression most frequently occurs due to
paternal deletion of this region (70% of PWS)2'3 or
less frequently due to maternal uniparental disomy
of chromosome 15 (25% of PWS)3"5. The remain-
ing 5% of PWS is caused by other structural
abnormalities on chromosome 15, such as micro-
deletion within the PWS imprinting gene centre3'6"8.
Patients with PWS have impaired growth
hormone (GH) responsiveness during stimulation
testing with GH releasing hormone and arginine ,
and numerous studies have described the benefits
of GH therapy in this syndrome10"16. Children with
PWS treated with GH (1 mg/m2/day) for 2 years
demonstrated normalisation of height standard
deviation score (SDS), faster growth in head
circumference, increased lean body mass accrual
and decreased body fat together with improved
language and cognitive functions15. In another
study GH was continued for a total of 4 years in
three cohorts receiving different doses of GH. The
benefit on growth velocity, body composition (lean
body mass) and resting energy expenditure was
noted with higher doses of GH (7 mg/m2/wk and
10.5 mg/m2/wk) but not with a dose of 2.1 mg/m2/
wk. Bone mineral density, however, improved in all
studied doses of GH12. Moreover, GH improved
sleep-related breathing disorders in children with
PWS in a study in which 19 out of 25 patients
showed improvement in the Apnoea/Hypopnoea
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Index (AHI) and Central Index (CI), but not of the
Obstructive Index (OI) \\hen polysomnography
6 months after commencement of GH \vas com-
pared to that of baseline17.
However, in a mortality review in patients with
PWS, the majority of sudden death was related to
respiratory pathology18'19 and this finding was also
supported by a study of KIGS, the Pfizer Inter-
national Growth Database °.
Aim and hypothesis
Few published studies have investigated the
optimal age for starting GH therapy in children
with PWS. The aim of this study was to determine
whether GH responsiveness was related to age at
commencement of GH. Our hypothesis was that the
earlier GH is started, the better the linear growth
and body composition compared to starting GH
therapy at older age. The biological rationale is that
GH sufficient children under 3 years of age have
greater height velocity. If children with PWS
younger than 3 years of age receive GH early, this
height velocity can be restored. Earlier commence-
ment of GH may lead to better body composition
because of earlier lean body mass accrual. It may
in turn result in higher energy expenditure since
lean tissues such as muscles have very active
metabolism.
METHODS
We performed a retrospective analysis on
growth data from the Ozgrow database of Australia
and New Zealand regarding children with PWS on
GH therapy. The Ozgrow database was established
by the Australasian Paediatric Endocrine Group
(APEG) in an attempt to collect data pertaining to
GH therapy in children in Australia and New
Zealand. GH therapy in Australia and New Zealand
is subsidised by the federal governments and all
applications for GH for various indications are
captured and entered into the database.
The eligibility criteria for GH therapy according
to the Department of Health and Aging of the
Australian Government are short stature (height
less than the first percentile as judged from the
World Health Organisation International References
for Growth which is based on data produced by the
Centers of Disease Control, U.S. Department of
Health and Human Services) and growth velocity
less than the 25th percentile for bone age; or
biochemical GH deficiency, that is peak GH level
less than 10 mU/1 in two challenge testings, plus a
growth velocity less than the 25th percentile. There
were no New Zealand patients included in this
report.
The GH prescribers, who are paediatric endo-
crinologists or experienced general paediatricians,
provide the diagnoses for short stature at the
application for GH. The database records the
diagnoses supplied by the GH prescribers as
Ozgrow diagnostic codes. Growth data of children
with the diagnostic code of 'Dysmorphic and
Genetic Syndromes - Prader-Willi Syndrome' were
extracted from the database.
The children with PWS who had GH treatment
or are currently receiving GH were analysed. Those
with no growth data for a minimum of 6 months or
who did not qualify for GH therapy were excluded
from the analysis. Sixteen patients (8 males and 8
females) who commenced GII before 3 years of age
(early group [EG]) and 40 (24 males and 16
females) who commenced after 3 years of age (late
group [LG]) were included in the study. Data up to
4 years after GH commencement were analysed.
The age- and sex-specific SDSs were calculated
for height and body mass index (BMI) using the
Centers for Disease Control 2000 reference data.
Change in height SDS (Δ height SDS) after 1, 2, 3
and 4 years of GH therapy was calculated from
baseline to assess the progressive nature of linear
growth; and change in BMI SDS (Δ BMI SDS) was
calculated for each year as a marker, albeit weak,
for change in body composition21'22. The Ozgrow
database records annual bone age assessment using
the Greulich and Pyle method. The ratio of bone
age to chronological age (BA:CA), which repre-
sents skeletal maturation in relation to chrono-
logical age, was calculated for each year.
Growth responsiveness was compared between
EG and LG. The mean values of height SDS, BMI
SDS, BA:CA, Δ height SDS, and Δ BMI SDS for
each year up to 4 years of GH therapy were used in
the comparison.
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Statistical analysis
For statistical analysis, two sample t-test and
Mann-Whitney U test were used for comparing
means of the two groups; and linear regression for
effect of age at commencement and height SDS at
baseline on improvement of height SDS at the end
of 4 years. All statistical procedures were per-
formed using SPSS 15.
RESULTS
Baseline values of height SDS, BMI SDS,
BA:CA and starting GH dose for the two groups
are shown in Table 1. Prior to commencement of
GH therapy, height SDS in the two groups was
similar but BA:CA of the EG was less than that of
LG, that is, the bone age delay was greater in the
EG (p = 0.0006). The mean starting GH dose was
TABLE 1
Comparison of variables in the early group (EG) and late group (LG) before commencing GH therapy
Male: Female
Ht SDS before GH therapy
BMI SDS before GH therapy
BA:CA before GH therapy
GH dose at commencement (mg/m2/wk)
Early group
n = 1 6
8:8
-2.68 (0.76)
-0.25(1.8)
0.53(0.19)
4.50 (0.97)
Late group
n = 40
24:16
-2.77 (0.75)
+0.67(1.77)
0.75(0.18)
5.10(1.14)
P
0.1260
0.6700
0.0900
0.0006
0.0700
Values of growth data and GH dose are shown as means (SD).
TABLE 2
Results of height SDS, BM1 SDS and BA:CA [mean (SD)] with GH therapy
in the early group (EG) and late group (LG)
Group
1st year
n
2nd year
n
3rd year
n
4th year
n
]
EG
-1.61
(0.67)
16
-1.12
(0.66)
15
-0.71
(0.66)
13
-0.70
(0.59)
11
Height SDS
LG
-2.17
(0.75)
40
-1.91
(0.75)
33
-1.68
(0.84)
29
-1.54
(0.72)
19
1
p EG
0.020 -0.37
(0.83)
13
0.002 -0.14
(1.18)
12
0.001 0.23
(1.21)
12
0.003 0.73(1.38)
10
BMI SDS
LG p
0.56 0.07
(1.72)
39
0.71 0.13
(1.76)
32
1.16 0.07
(1.55)
28
1.41(1.83) 0.31
18
EG
0.53
(0.22)
12
0.72
(0.20)
12
0.71
(0.17)
11
0.82
(0.16)
10
BA:CA
LG p
0.76 0.0000
(0.15)
38
0.78 0.0330
(0.21)
30
0.86 0.0023
(0.16)
23
0.89 0.0484
(0.17)
20
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Comparison of change in mean Ht SDS in EG and LG
**
EG
DLG
2 3 4
Years of GH therapy
Fig. I: Comparison of mean Δ height SDS with each year of GH therapy in the early group (EG) and late group (LG). *p = 0 001
** ρ = 0.002.
Baseline
Comparison of mean Ht SDS in EG and LG
1 yr 2y r 3yr 4y r
Years of GH therapy
Fig. 2: Comparison of mean height SDS with each year of GH therapy in the early group (EG) and late group (LG). * p = 0.020,
* p = 0.002,f p = 0.001, * ρ = 0.003.
Comparison of mean BMI SD in EG and LG
Years of GH therapy
Fig. 3: Comparison of mean BMI SDS with each year of GH therapy in the early group (EG) and late group (LG).
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Comparison of BA:CA in EG and LG
•MMi^b^_^^
Baseline
Year of GH Therapy
Fig. 4: Comparison of mean BA:CA with each year of GH therapy in the early group (EG) and late group (LG).
* p = 0.0000, * p = 0.0330, * p = 0.0023,f p = 0.0484.
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Fig. 5: Relationship between Δ height SDS at the first year of GH treatment and age of commencement.
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lower in the EG compared to that of the LG. The
mean Δ height SDS. mean height SDS, BMI SDS
and BA:CA between EG and LG for each year of
GH therapy are shown in Table 2 and Figures 1-4.
The Δ height SDS and mean height SDS were
greater in the EG compared to the LG (Figs. 1, 2,
Table 2). Regression analysis showed age of com-
mencement significantly influenced height SDS
after 4 years of GH therapy (p = 0.003), whereas
height SDS at baseline was not significantly related
(p = 0.178). Linear regression of Δ lit SDS at the
first year of GI1 therapy and age of commencement
of GH therapy for all the study population showed
a negative relationship (R2 = -0.316, ρ O.0001)
(Fig. 5). BA delay was more pronounced in the EG
and it did not mature beyond CA in either group
(see Table 2 and Fig. 4). Δ BMI SD for 4 years of
GH therapy did not reach statistical significance
(Fig- 3).
DISCUSSION
Our findings showed that improved linear
growth was associated with commencement of GH
before 3 years of age in children with PWS.
Although height SDS before GH therapy was
similar, after 4 years of GH therapy, the EG had
achieved height SDS of -0.70 (0.59) while the LG
achieved -1.54 (0.72) (p = 0.003). This clinical
benefit is also associated with a benefit in health
economics as smaller total doses of GI I for smaller
surface area are required for improved growth
outcomes in children less than 3 years of age.
The mean BMI of the LG was greater than that
of the EG (see Table 2 and Fig. 3) and it may be
due to poor feeding in younger children with PWS.
BMI increased with time even with GH therapy
(Fig. 3) but in this study it was not possible to
differentiate whether the increase in BMI was
related to increase in fat mass or lean mass. Many
studies11'13'23 reported that body composition im-
proved (decreased percent body fat and increased
lean body mass) with GH therapy (7-6 mg/m2/wk)
in children with PWS compared to untreated
children. As body composition is not routinely
recorded in the O/.grow database. BMI SDS was
used as an approximation. In our study, it was not
possible to compare the BMI of our GH treated
groups with PWS patients who did not receive GH
therapy.
Bone age assessments in the database are made
by different observers from various centres and it is
difficult to standardize, but our BA:CA findings
were consistently linear in both groups (see Fig. 4).
BA was more advanced in the LG before the com-
mencement of GH therapy and this phenomenon
has been described in the PWS literature4.
Although BA increased in both groups, it did not
mature beyond chronological age. I leight potential,
indicated by BA:CA, did not appear to be com-
promised by starting GI I early.
From our data it was found that the starting GH
dose used in the PWS literature was greater than
the current Australian practice15'25. It was not
possible to extrapolate whether a higher starting
dose in our cohort might result in better growth
outcome or increased development of adverse
effects.
No adverse effects related to GH therapy in
PWS, such as death °'26, deterioration of sleep-
related breathing disorders20'26'27, scoliosis28, dia-
betes mellitus20 and central adrenal failure29, are
recorded in the Ozgrow database. Since GH therapy
for children with PWS is subsidised by the
Australian Pharmaceutical Benefit Scheme, it is
highly recommended that a central mechanism
should be established to monitor such adverse
effects in children with PWS undergoing GH
therapy.
CONCLUSION
Within the limitations of a retrospective study,
our findings support the early commencement of
GH therapy in children with PWS. A prospective
study is needed to confirm such a benefit. The
height potential is not compromised by starting GH
early in PWS. As is evident from the literature, the
starting GH dose in current Australian practice for
children with PWS is lower than in international
centres. Furthermore, a central monitoring mecha-
nism for adverse effects of GI 1 in PWS is recom-
mended in Australia.
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